 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Mar 27, 2024 |
| Title |
DNA methylation as a therapeutic target in RB1 deficient and neuroendocrine prostate cancer and rational co-targeting with B7-H3 |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
Methylation profiling by high throughput sequencing
|
| Summary |
This SuperSeries is composed of the SubSeries listed below.
|
| |
|
| Overall design |
Refer to individual Series
|
| |
|
| Citation(s) |
37967200 |
| |
| Submission date |
Oct 18, 2022 |
| Last update date |
Mar 28, 2024 |
| Contact name |
Yasutaka Yamada |
| E-mail(s) |
yasutaka_yamada@dfci.harvard.edu
|
| Phone |
8574988355
|
| Organization name |
Dana-Farber Cancer Institute
|
| Department |
Medical Oncology
|
| Lab |
Beltran
|
| Street address |
44 Binney street
|
| City |
Boston |
| State/province |
MA |
| ZIP/Postal code |
02115 |
| Country |
USA |
| |
|
| Platforms (3) |
| GPL16791 |
Illumina HiSeq 2500 (Homo sapiens) |
| GPL20301 |
Illumina HiSeq 4000 (Homo sapiens) |
| GPL24676 |
Illumina NovaSeq 6000 (Homo sapiens) |
|
| Samples (31)
|
| GSM6657907 |
DNA methylation in 22Rv1 control |
| GSM6657908 |
DNA methylation in 22Rv1 sgRB1 control |
| GSM6657909 |
DNA methylation in 22Rv1 sgRB1 decitabine treated |
| GSM6657918 |
PM154, Control, rep1 |
| GSM6657919 |
PM154, Control, rep2 |
| GSM6657920 |
PM154, Control, rep3 |
| GSM6657921 |
PM154, DNMT1 knockout, rep1 |
| GSM6657922 |
PM154, DNMT1 knockout, rep2 |
| GSM6657923 |
PM154, DNMT1 knockout, rep3 |
| GSM6657924 |
PM154, DNMT3A knockout, rep1 |
| GSM6657925 |
PM154, DNMT3A knockout, rep2 |
| GSM6657926 |
PM154, DNMT3A knockout, rep3 |
| GSM6657927 |
PM154, Control, rep1 |
| GSM6657928 |
PM154, Control, rep2 |
| GSM6657929 |
PM154, Control, rep3 |
| GSM6657930 |
PM154, decitaine treated, rep1 |
| GSM6657931 |
PM154, decitaine treated, rep2 |
| GSM6657932 |
PM154, decitaine treated, rep3 |
| GSM6689313 |
22Rv1, Control, rep1 |
| GSM6689314 |
22Rv1, Control, rep3 |
| GSM6689315 |
22Rv1, CD276 knockout, rep1 |
| GSM6689316 |
22Rv1, CD276 knockout, rep3 |
| GSM6689317 |
22Rv1, WT-1 |
| GSM6689318 |
22Rv1, WT-2 |
| GSM6689319 |
22Rv1, WT-3 |
| GSM6689320 |
22Rv1, RB1 knockout-1 |
| GSM6689321 |
22Rv1, RB1 knockout-2 |
| GSM6689322 |
22Rv1, RB1 knockout-3 |
|
| This SuperSeries is composed of the following SubSeries:
|
| GSE216050 |
DNA methylation as a therapeutic target in RB1 deficient and neuroendocrine prostate cancer and rational co-targeting with B7-H3 [RRBS] |
| GSE216052 |
DNA methylation as a therapeutic target in RB1 deficient and neuroendocrine prostate cancer and rational co-targeting with B7-H3 [RNA-Seq 1] |
| GSE216053 |
DNA methylation as a therapeutic target in RB1 deficient and neuroendocrine prostate cancer and rational co-targeting with B7-H3 [RNA-Seq 2] |
| GSE216712 |
DNA methylation as a therapeutic target in RB1 deficient and neuroendocrine prostate cancer and rational co-targeting with B7-H3 [22Rv1sgCD276] |
| GSE216713 |
DNA methylation as a therapeutic target in RB1 deficient and neuroendocrine prostate cancer and rational co-targeting with B7-H3 [22Rv1sgRB1] |
|
| Relations |
| BioProject |
PRJNA891770 |
|
|
|
|
 |
Less...
More...